2. Apoptosis NF-κB MAPK/ERK Pathway Immunology/Inflammation
  3. RIP kinase NF-κB p38 MAPK TNF Receptor Interleukin Related
  4. RIPK1-IN-32

RIPK1-IN-32 is a RIPK inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC50 of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the RIPK1/NF-κB/MAPK pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis.

For research use only. We do not sell to patients.

RIPK1-IN-32

RIPK1-IN-32 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

RIPK1-IN-32 Related Antibodies

Top Publications Citing Use of Products

View All RIP kinase Isoform Specific Products:

View All Isoforms
RIPK1 RIPK2 RIPK3

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

RIPK1-IN-32 is a RIPK inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC50 of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the RIPK1/NF-κB/MAPK pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis[1].

IC50 & Target[1]

NF-κB

 

IL-6

 

RIPK1

 

In Vitro

RIPK1-IN-32 (Compound 12) (0-25 μM, 45-63 ℃) significantly inhibits the thermal degradation of RIPK1 in RAW264.7 macrophages[1].
RIPK1-IN-32 (2.5 μM) significantly diminishes p65 and c-fos nuclear translocation in RAW264.7 macrophages[1].
RIPK1-IN-32 (0.625-2.5 μM, 8 h) notably reduces d the levels of IL-6 and TNF-α in RAW 264.7 cells[1].
RIPK1-IN-32 (0.625-2.5 μM, 8 h) effectively hinders the LPS (HY-D1056B3)-induced activation of the RIPK1/NF-κB/MAPK pathway[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RIPK1-IN-32 Related Antibodies

ELISA Assay[1]

Cell Line: LPS-stimulated RAW 264.7 macrophages
Concentration: 0.625, 1.25, 2.5 μM
Incubation Time: 8 h, including 1 μg/mL LPS for 6 hours
Result: Significantly diminished the contents of IL-6 and TNF-α.

Western Blot Analysis[1]

Cell Line: LPS-stimulated RAW 264.7 macrophages
Concentration: 0.625, 1.25, 2.5 μM
Incubation Time: 8 h, including 1 μg/mL LPS for 6 hours
Result: Resulted in notable decreases in the levels of RIPK1, p-p65, and p-IκB suggesting an inhibition of NF-κB signaling.
Found to lower the protein levels of p-p38, p-ERK, and p-JNK which aligns with the suppression of MAPK signaling.
In Vivo

RIPK1-IN-32 (Compound 12) (1.25-5 mg/kg, i.v., single dose) provides considerable protective benefits against LPS-induced injuries in the liver, lung and kidney of mice subjected to sepsis[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: LPS injection into the tail vein to create a sepsis model established in Male BALB/c mice (18-20 g)[1]
Dosage: 1.25, 2.5 and 5 mg/kg
Administration: Intravenous injection (i.v.), single dose
Result: Markedly alleviated LPS-induced ALI.
Decreased the serum levels of ALT and AST.
Significantly diminished the contents of IL-6 and TNF-α.
Attenuated the damage to lung tissue and markedly lessened the pathological alterations noted in the kidneys subsequent.
Decreased in liver concentrations of RIPK1, p-p65, P-IκB, p-p38, p-ERK, and p-JNK.
Molecular Weight

754.05

Formula

C42H59NO7S2
SMILES

[H][C@@]12CC[C@@]([C@]3(C)[C@@](C4=C(C(O[C@H]4C3)=O)CC/C=C(C)/C)([H])C[C@H]5O)(C)[C@@]5([C@]1(CC[C@H]([C@H]2C)OC(CCSSCCC(NOCC6=CC=CC=C6)=O)=O)C)[H]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

RIPK1-IN-32 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

RIPK1-IN-32RIP kinaseNF-κBp38 MAPKTNF ReceptorInterleukin RelatedReceptor-interacting protein kinasesRIPKNuclear factor-κBNuclear factor-kappaBTumor Necrosis Factor ReceptorTNFRILFusidic acidSepsisAcute liver injuryAnti-inflammatory activityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
RIPK1-IN-32
Cat. No.:
HY-175007
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.